Definium Therapeutics (NASDAQ:DFTX) Announces Earnings Results, Misses Expectations By $0.89 EPS

Definium Therapeutics (NASDAQ:DFTX) issued its earnings results on Thursday. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89), FiscalAI reports.

Here are the key takeaways from Definium Therapeutics’ conference call:

• EMERGE phase III results were highly positive, with DT120 ODT producing an 8.1-point placebo-adjusted MADRS improvement in major depressive disorder at week six, statistically significant benefits from week one through week 12, and what management described as a favorable tolerability profile.
• Definium expects to report topline results from its VOYAGE phase III generalized anxiety disorder study during the week of August 10, 2026, followed by PANORAMA results in September; both trials completed enrollment and were estimated to have more than 99% power to detect the targeted treatment effect.
• The company raised approximately $758 million in net proceeds from an upsized public offering and ended the quarter with about $1.1 billion in cash, cash equivalents, and investments, which management believes can fund operations into 2030.
• Definium is expanding its commercial infrastructure ahead of a potential DT120 launch, including market access, sales, patient support, payer engagement, and clinician-awareness initiatives for GAD and MDD.
• Quarterly net loss increased to $159 million from $42.7 million a year earlier, while R&D and G&A expenses rose substantially as the company invested in clinical programs, personnel, and commercialization; an $86.2 million non-cash warrant valuation expense was a major contributor to the loss.

Definium Therapeutics Stock Performance

Shares of DFTX stock traded up $1.75 during mid-day trading on Thursday, hitting $46.14. The company’s stock had a trading volume of 1,769,473 shares, compared to its average volume of 1,770,657. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69. The company’s fifty day simple moving average is $37.00 and its 200-day simple moving average is $25.50. Definium Therapeutics has a 52 week low of $8.70 and a 52 week high of $49.20.

Insiders Place Their Bets

In other news, insider Matthew T. Wiley sold 2,867 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the sale, the insider owned 174,633 shares of the company’s stock, valued at $7,863,723.99. This trade represents a 1.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the completion of the sale, the chief financial officer owned 209,487 shares of the company’s stock, valued at $9,433,199.61. This represents a 1.42% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 48,096 shares of company stock worth $2,165,763. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DFTX. Russell Investments Group Ltd. boosted its position in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Definium Therapeutics by 56.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after buying an additional 3,020 shares during the period. Flagship Harbor Advisors LLC acquired a new position in Definium Therapeutics during the 4th quarter worth approximately $117,000. Caxton Associates LLP bought a new position in Definium Therapeutics in the third quarter worth approximately $126,000. Finally, Mercer Global Advisors Inc. ADV boosted its holdings in Definium Therapeutics by 10.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock worth $259,000 after acquiring an additional 2,079 shares in the last quarter. 27.91% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

DFTX has been the subject of several recent research reports. Canaccord Genuity Group set a $58.00 price objective on Definium Therapeutics and gave the company a “buy” rating in a research note on Tuesday, June 30th. Wells Fargo & Company began coverage on shares of Definium Therapeutics in a research report on Monday, July 27th. They set an “overweight” rating and a $68.00 target price on the stock. Leerink Partners set a $52.00 target price on shares of Definium Therapeutics and gave the stock an “outperform” rating in a report on Monday, June 22nd. Royal Bank Of Canada restated an “outperform” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Finally, JonesTrading raised their price target on shares of Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $54.85.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.